DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Identifying Outcomes for Sickle Cell Disease Clinical Trials is Aim of coreSCD
The Green Park Collaborative (GPC) is working with the Sickle Cell Disease Association of America (SCDAA) to develop a consensus of desired outcomes to be used in clinical studies evaluating new treatments for sickle cell disease (SCD).
The project, named coreSCD, aims to deliver a list of recommendations on the best outcomes to address the effectiveness and safety of potential therapies for SCD in clinical trials.
Multiple parties will be involved in the initiative, including patients and their families, clinicians, companies developing new SCD therapies, regulators (e.g., the U.S. Food and Drug Administration (FDA), healthcare payers (e.g., private healthcare plans and Medicaid), and sponsors from industry and academia.
One of the project leaders, the Green Park Collaborative (GPC), is a multi-stakeholder forum dedicated to creating disease and technology-specific recommendations to guide the production of evidence to inform both clinical and payment decisions. The forum will be a collaboration of a broad group of national and international partners.
Related Content
-
news & eventsNovo Nordisk obtains licence for sickle cell disease programNovo Nordisk inked a global licence deal...
-
news & eventsVoxelotor can Promote Long-Term Benefits in Teens, Adults With SCD, Latest Clinical Data ShowGlobal Blood Therapeutics’ lead therap...
-
news & eventsFDA Awards UNC Researcher $2M Grant to Study Kidney Disease in Sickle Cell AnemiaThe U.S. Food and Drug Administration (F...
-
education & researchTreatment for avascular necrosis of bone in people with sickle cell diseaseBACKGROUND: Avascular necrosis of bone ...
-
news & eventsGlobal Sickle Cell Disease Treatment Market 2019–2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squ...The global sickle cell disease treatment...
-
education & researchSocial Determinants of Health and Emergency Department Use Among Children With Sickle Cell DiseaseSickle cell disease (SCD) is associated ...
-
videos & visualsResearchers Develop Effective Treatment for Sickle Cell Anemiahttps://www.youtube.com/watch?v=7zceTJzH...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.